Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bet v 1 is the major allergen from birch (Betula verrucosa) pollen and serves as the prototype for the pathogenesis-related class 10 (PR-10) protein family. It is a small, cytosolic protein with a molecular weight of approximately 17–17.5 kDa. Bet v 1 adopts a characteristic fold consisting of a curved seven-stranded antiparallel β-sheet, two short α-helices, and an extended C-terminal helix that together create an enlarged inner cavity typical for PR-10 proteins. The large hydrophobic cavity functions as a ligand-binding site for various small molecules such as lipids, hormones, flavonoids, and siderophores. Multiple isoforms exist with minor sequence variations but significant differences in IgE-binding capacity. It is believed to play roles in plant defense mechanisms against pathogens or stress conditions. In its apo-form (unbound by iron), Bet v 1 can prime T cells toward Th2 responses, while holo-form (iron-bound) may suppress immune activation via induction of apoptosis in immune cells. Binding ligands stabilizes the conformation of Bet v 1.
N/A
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bet v 1.